World Journal of Hepatology - Baishideng Publishing Group

BPG is committed to discovery and dissemination of knowledge

Cited by in CrossRef

For:	Mak JWY, Law AWH, Law KWT, Ho R, Cheung CKM, Law MF. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era. World J Gastroenterol 2023; 29(33): 4942-4961 [PMID: 37731995 DOI: 10.3748/wjg.v29.i33.4942]
URL:	https://www.wjgnet.com/1948-5182/full/v29/i33/4942.htm

(179) (188) (0) (0) (0) (6) (1) (14183) (28)

Number	Citing Articles
1	Sergey Batskikh, Sergey Morozov. Reactivation of hepatitis B virus infection – an important aspect of multifaceted problem. World Journal of Gastroenterology 2024; 30(26): 3193-3197 doi: 10.3748/wjg.v30.i26.3193 Abstract(788) \| Core Tip(750) \| Full Article(HTML)(2651) \| Full Article (PDF)-489K(199) \| Full Article with Cover (PDF)-712K(159) \| Full Article (XML)-59K(164) \| Audio-383K(18) \| Peer-Review Report-215K(125) \| Answering Reviewers-281K(158) \| Times Cited (7) \| Total Visits (3602) \| Open
2	Daisuke Usuda, Yuki Kaneoka, Rikuo Ono, Masashi Kato, Yuto Sugawara, Runa Shimizu, Tomotari Inami, Eri Nakajima, Shiho Tsuge, Riki Sakurai, Kenji Kawai, Shun Matsubara, Risa Tanaka, Makoto Suzuki, Shintaro Shimozawa, Yuta Hotchi, Ippei Osugi, Risa Katou, Sakurako Ito, Kentaro Mishima, Akihiko Kondo, Keiko Mizuno, Hiroki Takami, Takayuki Komatsu, Tomohisa Nomura, Manabu Sugita. Current perspectives of viral hepatitis. World Journal of Gastroenterology 2024; 30(18): 2402-2417 doi: 10.3748/wjg.v30.i18.2402 Abstract(861) \| Core Tip(872) \| Full Article(HTML)(7396) \| Full Article (PDF)-531K(620) \| Full Article with Cover (PDF)-775K(251) \| Full Article (XML)-259K(176) \| Audio-524K(49) \| Peer-Review Report-311K(162) \| Answering Reviewers-140K(148) \| Times Cited (31) \| Total Visits (8998) \| Open
3	Jata Shankar Kumar, Deepanshu Khanna, Premashish Kar. Approach to diagnosis and management of reactivation of chronic hepatitis B. Future Virology 2024; 19(6-7) doi: 10.1080/17460794.2024.2356427
4	Goki Suda, Masatsugu Ohara, Masaru Baba, Yoshiya Yamamoto, Sonoe Yoshida, Qingjie Fu, Zijian Yang, Hidetaka Hosono, Daisuke Yokoyama, Shoichi Kitano, Takatsugu Tanaka, Akimitsu Meno, Naohiro Yasuura, Takashi Kitagataya, Naoki Kawagishi, Masato Nakai, Takuya Sho, Koji Ogawa, Osamu Maehara, Shunsuke Ohnishi, Takaaki Izumi, Ren Yamada, Takashi Meguro, Katsumi Terashita, Tomofumi Takagi, Jun Ito, Tomoe Kobayashi, Izumi Tsunematsu, Naoya Sakamoto. Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective study. Journal of Infection 2026; 92(4) doi: 10.1016/j.jinf.2026.106715
5	Andrea Galitzia, Monica Maccaferri, Francesca Romana Mauro, Roberta Murru, Roberto Marasca. Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents. Cancers 2024; 16(11) doi: 10.3390/cancers16111996
6	Yuxiao Zhao, Jingjing Guo, Xiran Wang, Lei Cao, Yi Xia, Haorui Shen, Ran Li, Ping Wu, Hongling Mi, Jing Zhang, Jianyong Li, Hailing Liu, Xiaoyan Qu, Lei Fan. Concurrent antiviral–immunochemotherapy strategy safely overcomes high hepatitis B viral load barrier in diffuse large B‐cell lymphoma: A multicentre cohort study. British Journal of Haematology 2026; doi: 10.1111/bjh.70584
7	Francesca Colapietro, Nicola Pugliese, Antonio Voza, Alessio Aghemo, Stella De Nicola. Risk of hepatitis B virus reactivation in oncological patients treated with tyrosine kinase inhibitors: A case report and literature analysis. World Journal of Gastroenterology 2024; 30(9): 1253-1256 doi: 10.3748/wjg.v30.i9.1253 Abstract(739) \| Core Tip(783) \| Full Article(HTML)(2319) \| Full Article (PDF)-346K(215) \| Full Article with Cover (PDF)-1824K(185) \| Full Article (XML)-35K(167) \| Audio-393K(15) \| Peer-Review Report-203K(138) \| Answering Reviewers-107K(130) \| Times Cited (9) \| Total Visits (3391) \| Open
8	Gen-Min Lin, Felicia Lin, Ming-Shen Dai, Wei-Nung Liu. Navigating the complex terrain of hepatitis B virus reactivation in the era of Bruton tyrosine kinase inhibitors. World Journal of Gastroenterology 2024; 30(21): 2748-2750 doi: 10.3748/wjg.v30.i21.2748 Abstract(749) \| Core Tip(703) \| Full Article(HTML)(1438) \| Full Article (PDF)-336K(153) \| Full Article with Cover (PDF)-1684K(139) \| Full Article (XML)-34K(115) \| Audio-364K(17) \| Peer-Review Report-310K(121) \| Answering Reviewers-77K(113) \| Times Cited (0) \| Total Visits (1845) \| Open
9	Tibor Bakacs, Imre Kovesdi, Rifaat Safadi. Leveraging Viruses for the Treatment of Viral Diseases and Cancer. 2026; doi: 10.1016/B978-0-443-29164-7.00002-9
10	James Tran, Calvin Zhou, Asis A Babun, Whinkie Leung, Ali Al-Sarray. Fatal Acute Liver Failure Associated With Presumed Hepatitis B Virus Reactivation During Rituximab Maintenance Therapy: A Case Report. Cureus 2026; doi: 10.7759/cureus.111434
11	Fadi Abu Baker, Mifleh Tatour, Ahmad Yehya, Tarek Saadi, Rawi Hazzan. Hepatitis B Screening, Antiviral Prophylaxis, and Reactivation Risk in Rituximab-Treated Patients: A 17-Year Population-Based Cohort Study Highlighting Current Practices and Gaps. Digestive Diseases and Sciences 2026; doi: 10.1007/s10620-026-09998-0
12	Haoru Jin, Zhibin Xu, Qing Ai, Qiangwei Huang, Xu Chen, Yongbei Luo, Peicong Hong, Yuan Qiu. Persistent lactic acidosis in ALK-positive anaplastic large cell lymphoma: a case report and literature review. Frontiers in Oncology 2026; 16 doi: 10.3389/fonc.2026.1744202
13	Jun-Ling Yang, Dong-Fu Li, Jing-Ru Ma, Qing-Zhu Yan, Hui Ma. Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies. World Journal of Gastroenterology 2024; 30(10): 1295-1312 doi: 10.3748/wjg.v30.i10.1295 Abstract(904) \| Core Tip(936) \| Full Article(HTML)(7387) \| Full Article (PDF)-1251K(452) \| Full Article with Cover (PDF)-1506K(606) \| Full Article (Word)-897K(18) \| Full Article (XML)-349K(162) \| Audio-407K(22) \| Peer-Review Report-310K(163) \| Answering Reviewers-316K(182) \| Times Cited (28) \| Total Visits (10031) \| Open
14	Guido Lancman, Kevin Song, Darrell White, Tina Crosbie, Ismail Sharif, Marianne Emond, Muhammad Saleem Raza, Martine Elias, Rayan Kaedbey, Michael P. Chu. Recommendations for the effective use of T-cell–redirecting therapies: a Canadian consensus statement. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1446995
15	Michele Barone. Risk of hepatic decompensation from hepatitis B virus reactivation in hematological malignancy treatments. World Journal of Gastroenterology 2024; 30(25): 3147-3151 doi: 10.3748/wjg.v30.i25.3147 Abstract(717) \| Core Tip(725) \| Full Article(HTML)(1696) \| Full Article (PDF)-365K(188) \| Full Article with Cover (PDF)-840K(162) \| Full Article (XML)-62K(133) \| Audio-1495K(13) \| Peer-Review Report-167K(127) \| Answering Reviewers-106K(156) \| Times Cited (0) \| Total Visits (2735) \| Open
16	Abdullah S. Shaikh, Susan C. Abraham, Lan S. Wang, Harrys A. Torres, Hao Chi Zhang. Viral Hepatitis B Reactivation With Delayed Cholestatic Effect Secondary to Acalabrutinib. ACG Case Reports Journal 2024; 11(6) doi: 10.14309/crj.0000000000001387
17	Piotr Chodup, Sophia L. Samodelov, Michele Visentin, Gerd A. Kullak‐Ublick. Drug‐Induced Liver Injury Associated With Emerging Cancer Therapies. Liver International 2025; 45(2) doi: 10.1111/liv.70002
18	Jiwoo Han, Kyun-Hwan Kim, Sang-Uk Seo. The Ubiquitin-Proteasome System in Hepatitis B Virus Infection and Hepatocarcinogenesis: Viral Manipulation and Therapeutic Targets. Journal of Microbiology and Biotechnology 2025; 35 doi: 10.4014/jmb.2508.08005
19	漫赵. Research Status of Antiviral Therapy for Chronic Hepatitis B. Advances in Clinical Medicine 2025; 15(04) doi: 10.12677/acm.2025.1541046
20	Chalid Assaf, Nina Booken, Edgar Dippel, Gabor Dobos, Hans‐Theodor Eich, Claus‐Detlev Klemke, Christina Mitteldorf, Jan P. Nicolay, Sebastian Theurich, Marion Wobser, Rudolf Stadler. Praxisempfehlungen für die Therapie und Überwachung von Mogamulizumab‐Patienten in Deutschland. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2025; 23(3) doi: 10.1111/ddg.15639_g
21	Hasmukh Jain, Neha Sharma, Devanshee Shah, Thomas Eipe, Netra Ghandade, Jayashree Thorat, Bhausaheb Bagal, Lingaraj Nayak, Alok Shetty, Anupa John, Sanjay K. Biswas, Gaurav Salunkhe, Sridhar Sundaram, Prachi S. Patil, Manju Sengar. Risk of Hepatitis B Reactivation Among ALL Patients With Occult Hepatitis B Infection. JCO Global Oncology 2026; 12(1) doi: 10.1200/GO-25-00262
22	Pasquale L. Fedele, Stephen Opat. Indolent lymphoma: addressing the needs of survivors. Leukemia & Lymphoma 2025; 66(6) doi: 10.1080/10428194.2025.2456970
23	Shin Yeu Ong, Thomas Chan, Eric Wai Choi Tse, Stephen Mulligan, Ping Chong Bee, Koji Izutsu, Jin Seok Kim, Bor Sheng Ko, Jianyong Li, Soo Chin Ng, Lalita Norasetthada, Lugui Qiu, Thanawat Rattanathammethee, Constantine Tam, Shuhua Yi, Huayuan Zhu, Yeow Tee Goh. The APLC expert consensus recommendations on the management of chronic lymphocytic leukaemia in Asia. Annals of the Academy of Medicine Singapore 2026; 55(3) doi: 10.47102/annals-acadmedsg.2025410
24	Arzu Altunçekiç Yıldırım, Celali Kurt, Burcu Ülküden, Yeliz Çetinkol. Hepatitis B Virus Reactivation with Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review. Viral Hepatitis Journal 2024; 30(1) doi: 10.4274/vhd.galenos.2024.2024-1-1
25	Chalid Assaf, Nina Booken, Edgar Dippel, Gabor Dobos, Hans‐Theodor Eich, Claus‐Detlev Klemke, Christina Mitteldorf, Jan P. Nicolay, Sebastian Theurich, Marion Wobser, Rudolf Stadler. Practical recommendations for therapy and monitoring of mogamulizumab patients in Germany. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2025; 23(3) doi: 10.1111/ddg.15639
26	Yongzheng Hu, Yue Zhang, Wei Jiang. Targeting hepatitis B virus-associated nephropathy: efficacy and challenges of current antiviral treatments. Clinical and Experimental Medicine 2025; 25(1) doi: 10.1007/s10238-025-01584-4
27	Bansi P Savaliya, Ramin Shekouhi, Fatima Mubarak, Harsheen K Manaise, Paola Berrios Jimenez, Gabrielle Kowkabany, Reed A Popp, Kyle Popp, Emmanuel Gabriel. Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors. World Journal of Gastroenterology 2024; 30(24): 3052-3058 doi: 10.3748/wjg.v30.i24.3052 Abstract(676) \| Core Tip(718) \| Full Article(HTML)(3137) \| Full Article (PDF)-395K(195) \| Full Article with Cover (PDF)-625K(159) \| Full Article (XML)-73K(130) \| Audio-289K(11) \| Peer-Review Report-361K(151) \| Answering Reviewers-140K(114) \| Times Cited (3) \| Total Visits (4115) \| Open
28	Matteo Tonnini, Clara Solera Horna, Luca Ielasi. Prevention of hepatitis B reactivation in patients with hematologic malignancies treated with novel systemic therapies: Who and Why?. World Journal of Gastroenterology 2024; 30(5): 509-511 doi: 10.3748/wjg.v30.i5.509 Abstract(715) \| Core Tip(711) \| Full Article(HTML)(2033) \| Full Article (PDF)-335K(238) \| Full Article with Cover (PDF)-3335K(207) \| Full Article (Word)-106K(26) \| Full Article (XML)-28K(159) \| Audio-160K(14) \| Peer-Review Report-198K(160) \| Answering Reviewers-52K(144) \| Times Cited (2) \| Total Visits (2663) \| Open